Selected trials highlighting predictive utility of geriatric assessment measures for older adults with hematologic malignancy
| Disease type/setting . | No. patients . | Outcomes predicted . | Measures . |
|---|---|---|---|
| Chronic lymphocytic leukemia8 | 75 | Overall survival | Low objective physical performance (Timed Up and Go) and cognition |
| Multiple myeloma10 | 869 | Overall survival, nonhematologic adverse events, treatment discontinuation | Composite fitness score (ADLs, IADLs, comorbidity, age) |
| Acute myeloid leukemia9 | 74 | Overall survival | Low objective physical function (Short Physical Performance Battery) and cognition |
| Acute myeloid leukemia/myelodysplastic syndrome7 | 195 | Overall survival | ADLs and fatigue in nonintensively treated patients |
| Myelodysplastic syndrome14 | 98 | Overall survival and treatment duration. | IADLs and comorbidity associated with overall survival. IADLs, cognition, and low objective physical function (Timed Up and Go) associated with treatment duration. |
| Myelodysplastic syndrome19 | 455 | Overall survival | Clinical frailty score and comorbidity |
| Non-Hodgkin lymphoma22 | 143 | Overall survival | IADLs and comorbidity |
| Non-Hodgkin lymphoma32 | 173 | Overall survival | Composite fitness score (ADLs, IADLs, comorbidity, age) |
| Non-Hodgkin lymphoma33 | 99 | Overall survival, response rates, progression-free survival | IADLs, composite score (albumin, comorbidity, age) |
| Non-Hodgkin lymphoma23 | 70 | Overall survival, early discontinuation of chemotherapy | Nutritional status associated with both outcomes |
| Hodgkin lymphoma33 | 48 | Progression-free survival | Loss of IADLs |
| Bone marrow transplantation (mixed population)12 | 203 | Overall survival | IADLs, gait speed, comorbidity, mental health |
| Bone marrow transplantation (mixed population)24 | 184 | Overall survival | IADLs, physical subscale of Functional Assessment of Cancer Therapy Bone Marrow Transplant |
| Bone marrow transplantation (mixed population, allogeneic transplantation)21 | 106 | Overall survival | Low objective physical performance (Timed Up and Go), fatigue |
| Bone marrow transplantation (multiple myeloma)29 | 100 | Hospital readmission, hospital length of stay | Decreased grip strength, anxiety/depression, falls, and weight loss associated with readmission. Objective (Short Physical Performance Battery) and self-reported physical function associated with length of stay. |
| Mixed population (myelodysplastic syndrome, leukemia, multiple myeloma, lymphoma)34 | 314 | Overall survival, unplanned hospitalization | Slower gait speed associated with increase mortality and unplanned hospitalizations |
| Lower grip strength associated with shorter survival |
| Disease type/setting . | No. patients . | Outcomes predicted . | Measures . |
|---|---|---|---|
| Chronic lymphocytic leukemia8 | 75 | Overall survival | Low objective physical performance (Timed Up and Go) and cognition |
| Multiple myeloma10 | 869 | Overall survival, nonhematologic adverse events, treatment discontinuation | Composite fitness score (ADLs, IADLs, comorbidity, age) |
| Acute myeloid leukemia9 | 74 | Overall survival | Low objective physical function (Short Physical Performance Battery) and cognition |
| Acute myeloid leukemia/myelodysplastic syndrome7 | 195 | Overall survival | ADLs and fatigue in nonintensively treated patients |
| Myelodysplastic syndrome14 | 98 | Overall survival and treatment duration. | IADLs and comorbidity associated with overall survival. IADLs, cognition, and low objective physical function (Timed Up and Go) associated with treatment duration. |
| Myelodysplastic syndrome19 | 455 | Overall survival | Clinical frailty score and comorbidity |
| Non-Hodgkin lymphoma22 | 143 | Overall survival | IADLs and comorbidity |
| Non-Hodgkin lymphoma32 | 173 | Overall survival | Composite fitness score (ADLs, IADLs, comorbidity, age) |
| Non-Hodgkin lymphoma33 | 99 | Overall survival, response rates, progression-free survival | IADLs, composite score (albumin, comorbidity, age) |
| Non-Hodgkin lymphoma23 | 70 | Overall survival, early discontinuation of chemotherapy | Nutritional status associated with both outcomes |
| Hodgkin lymphoma33 | 48 | Progression-free survival | Loss of IADLs |
| Bone marrow transplantation (mixed population)12 | 203 | Overall survival | IADLs, gait speed, comorbidity, mental health |
| Bone marrow transplantation (mixed population)24 | 184 | Overall survival | IADLs, physical subscale of Functional Assessment of Cancer Therapy Bone Marrow Transplant |
| Bone marrow transplantation (mixed population, allogeneic transplantation)21 | 106 | Overall survival | Low objective physical performance (Timed Up and Go), fatigue |
| Bone marrow transplantation (multiple myeloma)29 | 100 | Hospital readmission, hospital length of stay | Decreased grip strength, anxiety/depression, falls, and weight loss associated with readmission. Objective (Short Physical Performance Battery) and self-reported physical function associated with length of stay. |
| Mixed population (myelodysplastic syndrome, leukemia, multiple myeloma, lymphoma)34 | 314 | Overall survival, unplanned hospitalization | Slower gait speed associated with increase mortality and unplanned hospitalizations |
| Lower grip strength associated with shorter survival |